Search results for " Tumor-Infiltrating"

showing 10 items of 62 documents

CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes

2013

CD39 is an ectoenzyme, present on different immune cell subsets, which mediates immunosuppressive functions catalyzing ATP degradation. It is not known whether CD39 is expressed and implicated in the activity of CD8+ regulatory T lymphocytes (Treg). In this study, CD39 expression and function was analyzed in both CD8+ and CD4+CD25hi Treg from the peripheral blood of healthy donors as well as from tumor specimens. CD39 was found expressed by both CD8+ (from the majority of healthy donors and tumor patients) and CD4+CD25 hi Treg, and CD39 expression correlated with suppression activity mediated by CD8+ Treg. Importantly, CD39 counteraction remarkably inhibited the suppression activity of CD8+…

CD4-Positive T-LymphocytesCancer ResearchImmunologyAntineoplastic Agentschemical and pharmacologic phenomenaCD8-Positive T-LymphocytesBiologyT-Lymphocytes RegulatoryImmune toleranceAntineoplastic AgentLymphocytes Tumor-InfiltratingImmune systemAntigenAntigens CDImmune TolerancemedicineHumansIndoleamine-Pyrrole 23-DioxygenaseImmunology and AllergyCell ProliferationCD39Tumor microenvironmentCell growthApyraseInterleukin-2 Receptor alpha SubunitCD8-Positive T-LymphocyteTumor immune escapePhenotypePhenotypeCD39 CD8+ Treg Tumor immune escape ToleranceMicroscopy FluorescenceOncologyMechanism of actionCD4-Positive T-LymphocyteImmunologyCD8+ Tregmedicine.symptomToleranceCD8HumanCancer Immunology, Immunotherapy
researchProduct

Antigen-Driven T-Cell Selection in Patients with Cervical Cancer as Evidenced by T-Cell Receptor Analysis and Recognition of Autologous Tumor

2002

ABSTRACTWe characterized the T-cell receptor (TCR) repertoire in freshly harvested tumor lesions, in short-term-expanded CD4+tumor infiltrating lymphocytes (TIL) as well as in CD4+and CD8+peripheral blood lymphocytes (PBL) from three patients with cervical cancer. Skewing of the T-cell repertoire as defined by measuring the length of the complementarity-determining region 3 (CDR3) of the TCR VA and VB chains was observed in CD8+PBL, in freshly harvested tumor tissue, as well as in CD4+TIL. Comparative analysis of the TCR repertoire revealed unique monoclonal TCR transcripts within the tumor lesion which were not present in PBL, suggesting selection of TCR clonotypes due to antigenic stimula…

CD4-Positive T-LymphocytesMicrobiology (medical)medicine.medical_treatmentClinical BiochemistryImmunologyReceptors Antigen T-CellUterine Cervical Neoplasmschemical and pharmacologic phenomenaCD8-Positive T-LymphocytesBiologyEpitopeEpitopesLymphocytes Tumor-InfiltratingImmune systemAntigenAntigens NeoplasmExperimental Clinical InvestigationmedicineHumansImmunology and AllergyTumor-infiltrating lymphocytesT-cell receptorhemic and immune systemsImmunotherapyComplementarity Determining RegionsImmunologyT cell selectionFemaleCD8Clinical and Vaccine Immunology
researchProduct

Human Papillomavirus Type 33 E7 Peptides Presented by HLA-DR*0402 to Tumor-Infiltrating T Cells in Cervical Cancer

2000

ABSTRACTSeveral characteristics make human papillomavirus (HPV) amenable to vaccination. Anti-HPV-directed vaccines are based on the observation that HPV E6 and E7 oncoproteins are constitutively expressed in HPV-positive cervical cancer and may serve as tumor rejection antigens. Five HPV types (16, 18, 31, 33, and 45) account for 80% of cervical cancer. Until now, the type of immune response capable of mediating an effective antitumor response has not been defined. In order to define the anticancer-directed immune response in situ, we characterized CD4+and CD8+sorted T cells from peripheral blood lymphocytes, freshly harvested tumor tissue, and tumor-infiltrating lymphocytes (TIL) from a p…

CD4-Positive T-LymphocytesT-LymphocytesMolecular Sequence DataImmunologyAntigen presentationReceptors Antigen T-CellUterine Cervical NeoplasmsCD8-Positive T-LymphocytesMajor histocompatibility complexMicrobiologyEpitopeEpitopesInterferon-gammaLymphocytes Tumor-InfiltratingImmune systemAntigenVirologymedicineHumansAmino Acid SequencePapillomaviridaePapillomaviridaeCervical cancerAntigen PresentationbiologyHLA-DR AntigensOncogene Proteins ViralFlow Cytometrymedicine.diseasebiology.organism_classificationImmunohistochemistryPeptide FragmentsInsect ScienceImmunologybiology.proteinCancer researchPathogenesis and ImmunityFemaleCD8Journal of Virology
researchProduct

Monoclonal TCR mRNA transcripts are preferentially detected in the TCR variable alpha chain in CD8(+) T-lymphocytes: implications for immunomonitorin…

1999

Clinical trials have started to implement tumor-associated antigens in the form of antigenic peptides in order to augment CD8(+) T-cell responses directed against autologous cancer cells. One of the surrogate markers for successful immunization is the characterization of T-lymphocytes reacting to the immunizing peptide as determined by CDR3-length and DNA-sequence analysis. Most of the recent studies examining ex vivo T-cell responses in patients with cancer have focussed on expression and prevalence of the TCR Beta variable region, predominantly in non-sorted T-cell populations. Here, we show that clonal T-cell receptors (TCRs), as defined by DNA-fragment analysis and DNA-sequencing, appea…

CD4-Positive T-Lymphocytesmedicine.medical_treatmentPopulationUterine Cervical Neoplasmschemical and pharmacologic phenomenaCD8-Positive T-LymphocytesBiologyLymphocytes Tumor-InfiltratingAntigenAntigens NeoplasmNeoplasmsGeneticsmedicineHumansRNA Messengereducationeducation.field_of_studyT-cell receptorCancerhemic and immune systemsGeneral MedicineImmunotherapymedicine.diseaseMolecular biologyClone CellsImmunologyMonoclonalFemaleGenes T-Cell Receptor alphaCD8Alpha chainInternational Journal of Molecular Medicine
researchProduct

Genetic evolution of T-cell resistance in the course of melanoma progression

2014

Abstract Purpose: CD8+ T lymphocytes can kill autologous melanoma cells, but their activity is impaired when poorly immunogenic tumor phenotypes evolve in the course of disease progression. Here, we analyzed three consecutive melanoma lesions obtained within one year of developing stage IV disease for their recognition by autologous T cells. Experimental Design: One skin (Ma-Mel-48a) and two lymph node (Ma-Mel-48b, Ma-Mel-48c) metastases were analyzed for T-cell infiltration. Melanoma cell lines established from the respective lesions were characterized, determining the T-cell–stimulatory capacity, expression of surface molecules involved in T-cell activation, and specific genetic alteratio…

Cancer ResearchB7 Antigensmedicine.medical_treatmentMedizinGene ExpressionT-Lymphocyte Subsetshemic and lymphatic diseasesCluster AnalysisLymphocytesNeoplasm MetastasisLymph nodeMelanomaTumorImmunogenicityMelanomaSingle Nucleotidemedicine.anatomical_structurePhenotypeButorphanolOncologyDisease ProgressionCytokinesEvolutionT cellHuman leukocyte antigenBiologyPolymorphism Single NucleotideArticleCell LineEvolution MolecularLymphocytes Tumor-InfiltratingCell Line TumormedicineHumansGenetic Predisposition to DiseaseTumor-InfiltratingAllelePolymorphismneoplasmsAllelesNeoplasm StagingHistocompatibility Antigens Class IMolecularImmunotherapymedicine.diseaseAlleles; B7 Antigens; Butorphanol; Cell Line Tumor; Cluster Analysis; Cytokines; Disease Progression; Gene Expression; Genetic Predisposition to Disease; Histocompatibility Antigens Class I; Humans; Lymphocytes Tumor-Infiltrating; Melanoma; Mutation; Neoplasm Metastasis; Neoplasm Staging; Phenotype; Polymorphism Single Nucleotide; T-Lymphocyte Subsets; beta 2-Microglobulin; Evolution Molecular; Oncology; Cancer ResearchImmunologyMutationbeta 2-MicroglobulinCD8
researchProduct

T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Mod…

2021

AbstractTumors undergo dynamic immunoediting as part of a process that balances immunologic sensing of emerging neoantigens and evasion from immune responses. Tumor-infiltrating lymphocytes (TIL) comprise heterogeneous subsets of peripheral T cells characterized by diverse functional differentiation states and dependence on T-cell receptor (TCR) specificity gained through recombination events during their development. We hypothesized that within the tumor microenvironment (TME), an antigenic milieu and immunologic interface, tumor-infiltrating peripheral T cells could reexpress key elements of the TCR recombination machinery, namely, Rag1 and Rag2 recombinases and Tdt polymerase, as a poten…

Cancer ResearchDatasets as TopicT-Cell Antigen Receptor SpecificityCD8-Positive T-LymphocytesMice0302 clinical medicineTumor MicroenvironmentRecombinaseT-cell receptorBreastRNA-SeqT Cells T Cell Receptor Recombination/Revision Machinery Tumor MicroenvironmentCancerAged 80 and overMice KnockoutRecombination GeneticNuclear Proteinshemic and immune systemsMiddle AgedDNA-Binding Proteins030220 oncology & carcinogenesisFemaleSingle-Cell AnalysisMutL Protein Homolog 1AdultImmunologyReceptors Antigen T-CellT cellsBreast Neoplasmschemical and pharmacologic phenomenaSettore MED/08 - Anatomia PatologicaBiologyRecombination-activating gene03 medical and health sciencesLymphocytes Tumor-InfiltratingImmune systemAntigenDNA NucleotidylexotransferaseRAG2AnimalsHumansSettore MED/05 - Patologia ClinicaAgedHomeodomain ProteinsTumor microenvironmentT-cell receptorDisease Models AnimalImmunoeditingCancer researchDNA Damage030215 immunology
researchProduct

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients?

2019

e14035 Background: The immune response to melanoma has been shown to be locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk (infiltrating the entire base of the invasive tumor), non-brisk (infiltrating only focally) and absent. Several studies showed that greater presence of TILs, especially brisk, in primary melanoma is associated with a better prognosis and a higher survival rate. Since recent studies revealed an association between PD-1/PD-L1 expression levels and tumor response, the aim of our study was to investigate the correlation between plasma PD-1 and presence/absence/class of TILs in metastatic melanoma patients. Methods: The plasm…

Cancer ResearchMetastatic melanomaTumor-infiltrating lymphocytesbusiness.industryMelanomahemic and immune systemschemical and pharmacologic phenomenamedicine.disease03 medical and health sciences0302 clinical medicineImmune systemOncology030220 oncology & carcinogenesisCancer researchmedicineplasma PD-1 tumor-infiltrating lymphocytes metastatic melanomabusiness030215 immunologyJournal of Clinical Oncology
researchProduct

Nanofitins targeting heat shock protein 110: an innovative immunotherapeutic modality in cancer.

2021

The presence of an inactivating heat shock protein 110 (HSP110) mutation in colorectal cancers has been correlated with an excellent prognosis and with the ability of HSP110 to favor the formation of tolerogenic (M2-like) macrophages. These clinical and experimental results suggest a potentially powerful new strategy against colorectal cancer: the inhibition of HSP110. In this work, as an alternative to neutralizing antibodies, Nanofitins (scaffold ~7 kDa proteins) targeting HSP110 were isolated from the screening of a synthetic Nanofitin library, and their capacity to bind (immunoprecipitation, biolayer interferometry) and to inhibit HSP110 was analyzed in vitro and in vivo. Three Nanofiti…

Cancer ResearchMice03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmune systemPeptide LibraryIn vivoCell Line TumorHeat shock proteinTumor MicroenvironmentmedicineAnimalsHumansCytotoxic T cellHSP110 Heat-Shock Proteinssmall peptide moleculesTumor microenvironmentanticancer targeted therapybiologyChemistryMacrophagesCancer[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesmedicine.diseaseXenograft Model Antitumor AssaysPeptide FragmentsIn vitro3. Good healthNanofitinsOncologyPositron-Emission Tomography030220 oncology & carcinogenesisbiology.proteinCancer researchFemaleAntibodyColorectal NeoplasmsHSP110
researchProduct

Exome Sequencing to Predict Neoantigens in Melanoma

2015

Abstract The ability to use circulating peripheral blood cells and matched tumor sequencing data as a basis for neoantigen prediction has exciting possibilities for application in the personalized treatment of cancer patients. We have used a high-throughput screening approach, combining whole-exome sequence data, mRNA microarrays, and publicly available epitope prediction algorithm output to identify mutated proteins processed and displayed by patient tumors and recognized by circulating immune cells. Matched autologous melanoma cell lines and peripheral blood mononuclear cells were used to create mixed lymphocyte tumor cell cultures, resulting in an expansion of tumor-reactive T cells to u…

Cancer Researchbusiness.industryMelanomaLymphocyteImmunologyEpitopes T-LymphocyteDendritic cellCD8-Positive T-Lymphocytesmedicine.diseasePeripheral blood mononuclear cellEpitopeInterferon-gammaLymphocytes Tumor-Infiltratingmedicine.anatomical_structureImmune systemAntigenAntigens NeoplasmMutationImmunologyHumansMedicineExomebusinessMelanomaExome sequencingCancer Immunology Research
researchProduct

Prognostic significance of spatial and density analysis of T lymphocytes in colorectal cancer.

2022

Abstract Background Although high T cell density is a strong favourable prognostic factor in colorectal cancer, the significance of the spatial distribution of T cells is incompletely understood. We aimed to evaluate the prognostic significance of tumour cell-T cell co-localisation and T cell densities. Methods We analysed CD3 and CD8 immunohistochemistry in a study cohort of 983 colorectal cancer patients and a validation cohort (N = 246). Individual immune and tumour cells were identified to calculate T cell densities (to derive T cell density score) and G-cross function values, estimating the likelihood of tumour cells being co-located with T cells within 20 µm radius (to derive T cell p…

Cancer ResearchkasvaimetIDENTIFICATIONtumour immunologyT-LymphocytesBIOMARKERS3122 Cancerscolorectal cancerCD8-Positive T-Lymphocytes3126 Surgery anesthesiology intensive care radiologyPrognosisT-imusolutimmunohistokemiaLymphocytes Tumor-InfiltratingOncologyBRAF MUTATIONBiomarkers TumorHumanssyöpätauditLymphocyte CountColorectal NeoplasmsIMMUNOSCOREcancer microenvironmentpaksusuolisyöpäBritish journal of cancer
researchProduct